Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trimethoprim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | DHFR | P00374 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethoprim SCHEMBL4731560 | 0.85 | CYP2C19 (0.59) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL958034 | 0.85 | DHFR (0.63) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL30345188 | 0.85 | CYP2C19 (0.61) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL29357344 | 0.85 | DHFR (0.58) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL11245112 | 0.84 | ALDH1A1 (0.62) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL18094237 | 0.84 | DHFR (0.57) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| SCHEMBL9732799 | 0.83 | DHFR (0.58) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL29420800 | 0.82 | DHFR (0.59) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL4182820 | 0.82 | DHFR (0.72) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 | |
| Trimethoprim SCHEMBL28846304 | 0.81 | DHFR (0.63) | ALDH1A1DHFRMEN1SLC22A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2417 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101906-A1 | MIXTURES FOR FUNGAL CONTROL IN CORN | CORTEVA AGRISCIENCE LLC (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4742259-A1 | METHOD AND DEVICE FOR PREDICTING THE APPROPRIATENESS OF ANTIBIOTIC USE IN PATIENTS WITH INFECTIOUS DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122029285-A | Methods of treating hypertrophic cardiomyopathy with AAV gene therapy vectors and therapeutic formulations | 迪纳柯公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260128145-A1 | METHOD AND DEVICE FOR PREDICTING THE APPROPRIATENESS OF ANTIBIOTIC USE IN PATIENTS WITH INFECTIOUS DISEASES | UNIV YONSEI IACF (KR) | 2026-05-07 | — | — | US | claimed |
| EP-4736859-A1 | ANTIBIOTIC COMPOSITIONS | University of Galway (IE) | 2026-05-06 | — | — | EP | claimed |
| EP-4197165-B1 | SYSTEMS AND METHODS FOR COMPRESSING A SID LIST | CISCO TECH INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4713011-A1 | METHODS OF TREATING CD20 EXPRESSING B-CELL CANCERS | Genmab A/S (DK) | 2026-03-25 | — | — | EP | claimed |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| US-20260001460-A1 | TRIM ATTACHMENT | ADIENT US LLC (US) | 2026-01-01 | — | — | US | claimed |
| US-20060228357-A1 | dimerization and docking domains; fusion proteins | IBC PHARMACEUTICALS, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006107786-A2 | IMPROVED STABLY TETHERED STRUCTURES OF DEFINED COMPOSITIONS WITH MULTIPLE FUNCTIONS OR BINDING SPECIFICITIES | IBC PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | claimed |
| WO-2006107617-A2 | METHODS FOR GENERATING STABLY LINKED COMPLEXES COMPOSED OF HOMODIMERS, HOMOTETRAMERS OR DIMERS OF DIMERS AND USES | IBC PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | claimed |
| US-20050045183-A1 | Methods and devices for occluding body lumens and/or for delivering therapeutic agents | OVION, INC. (US) | 2005-03-03 | — | — | US | claimed |
| EP-1290220-A4 | GENETIC DIAGNOSIS FOR QT PROLONGATION RELATED ADVERSE DRUG REACTIONS | UNIV GEORGETOWN (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030211500-A1 | Genetic diagnosis for qt prolongation related adverse drug reactions | WOOSLEY, RAYMOND L | 2003-11-13 | — | — | US | claimed |
| WO-2003053347-A2 | GALLIUMCOMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT MYCOBACTERIAL INFECTIONS | BERNSTEIN LAWRENCE R (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1290220-A1 | GENETIC DIAGNOSIS FOR QT PROLONGATION RELATED ADVERSE DRUG REACTIONS | GEORGETOWN UNIVERSITY (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020068761-A1 | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections | BERNSTEIN LAWRENCE R (US) | 2002-06-06 | — | — | US | claimed |
| WO-2001079554-A1 | GENETIC DIAGNOSIS FOR QT PROLONGATION RELATED ADVERSE DRUG REACTIONS | GEORGETOWN UNIVERSITY (US) | 2001-10-25 | — | — | WO | claimed |